Cancer combo trial pulled before enrolling a single patient

NCT ID NCT03402880

Terminated Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen May 31, 2026 · Last updated Jun 15, 2026 · Updated 3 times

Summary

This study was designed to test whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and epacadostat (a drug that boosts immune cell activity)—could shrink tumors in people with extensive stage small cell lung cancer who had already received platinum-based chemotherapy. The trial was withdrawn before any participants were enrolled, so no results are available. It was planned for around 0 participants and did not proceed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
City of Hope South Pasadena

South Pasadena, California, 91030, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Conditions

Explore the condition pages connected to this study.

EXTENSIVE STAGE SMALL CELL LUNG CARCINOMA